NeuBase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:12 pm EST
NeuBase Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 1.82 million compared to USD 7.63 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 4.73 a year ago. Diluted loss per share from continuing operations was USD 0.66 compared to USD 4.73 a year ago.
For the nine months, net loss was USD 9.36 million compared to USD 26.05 million a year ago. Basic loss per share from continuing operations was USD 4.57 compared to USD 16.08 a year ago. Diluted loss per share from continuing operations was USD 4.57 compared to USD 16.08 a year ago.